🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Treatment-Refractory Solid Tumors

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692Phase 1, Phase 21 site📍 Boadilla del Monte Fundación de investigación HM · Tests: Olaparib; 177Lu-DOTATATE A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies NCT04678648Phase 13 sites📍 Los Angeles📍 Denver📍 Nashville RasCal Therapeutics, Inc. · Tests: RSC-1255 Dose Escalation, RSC-1255 Dose Expansion CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors NCT05733000Phase 21 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453Phase 1, Phase 213 sites📍 New York📍 New York📍 Huntersville GI Innovation, Inc. · Tests: GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A YH02 Injection for Intra-tumor Injection Therapy in Advanced Solid Tumors With Unresponsive or Failure-Treated Cases NCT07697937Phase 21 site📍 Tianjin Tianjin First Central Hospital · Tests: YH-02 Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors NCT06320405Phase 1, Phase 21 site📍 Portland OHSU Knight Cancer Institute · Tests: Axatilimab, Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours NCT06430502NA1 site📍 Wuxi Wuxi People's Hospital · Tests: Tumor Treatment Vaccine; PD-1/L1 inhibitors TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma NCT07189195Phase 11 site📍 Sacramento University of California, Davis · Tests: TR-002 CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors NCT05410717Phase 11 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors NCT03686124Phase 1, Phase 221 sites📍 Stanford📍 Aurora📍 Miami Immatics US, Inc. · Tests: IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product, Nivolumab, IMADetect® KSH01-TCRT Solid Tumors NCT05539833EARLY Phase 11 site📍 Nanning TCRx Therapeutics Co.Ltd · Tests: KSH01 injection Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors NCT06940349Phase 1, Phase 21 site📍 Petah Tikva Rabin Medical Center · Tests: Palbociclib, Sunitinib GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours NCT07297667Phase 14 sites📍 Calgary📍 Ottawa📍 Toronto Canadian Cancer Trials Group · Tests: Fludarabine, Cyclophosphamide, GCAR1 Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors NCT03934372Phase 1, Phase 223 sites📍 Ghent📍 Paris📍 Paris Incyte Biosciences International Sàrl · Tests: Ponatinib IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel, Capivasertib RAPA-201 Therapy of Solid Tumors NCT05144698Phase 1, Phase 21 site📍 Hackensack Rapa Therapeutics LLC · Tests: RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody) Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors NCT06014502Phase 113 sites📍 Gilbert📍 Orange📍 Santa Monica ImmunoGenesis · Tests: IMGS-001 Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors. NCT06173219Phase 1, Phase 21 site📍 Beijing China-Japan Friendship Hospital · Tests: Radiotherapy combined with immunotherapy Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma NCT07598955Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Cyclophosphamide, Fludarabine, EB-CAR30-NK, EB-CAR5-NK, EB-CARMSLN-NK A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy NCT06549907n/a1 site📍 Beijing Peking University Cancer Hospital & Institute · Tests: Multi-omics testing, MRI A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. NCT07016997Phase 12 sites📍 Nagaizumicho📍 Chuo-Ku Chiome Bioscience Inc. · Tests: CBA-1535, CBA-1535+Pembrolizumab A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea) NCT07190833Phase 12 sites📍 Busan📍 Busan Bionoxx Inc. · Tests: OTS-412, Hydroxyurea (HU), Hydroxyurea (HU), Hydroxyurea (HU), Hydroxyurea (HU) Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling NCT05857969Phase 11 site📍 Miami Florida International University · Tests: Functional Precision Medicine Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer NCT07589543Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DUALNK, Cyclophosphamide, Fludarabine A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment NCT04928677Phase 15 sites📍 Los Angeles📍 Atlanta📍 Boston Memorial Sloan Kettering Cancer Center · Tests: Codrituzumab SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors NCT06873659Phase 111 sites📍 Beijing📍 Beijing📍 Beijing Qurgen Inc. · Tests: SON-DP Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma NCT07502287Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DTNB-NK, Fludarabine, Cyclophosphamide SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors NCT06936748Phase 21 site📍 Nanchang Second Affiliated Hospital of Nanchang University · Tests: Spatially Fractionated Radiation Therapy Followed by Sequential Hypofractionated or Conventional Fractionated Radiother… Study of CMTS1215 Injection in Patients With Solid Tumors NCT07556276Phase 1, Phase 21 site📍 Nanjing The Second Hospital of Nanjing Medical University · Tests: CMTS1215 Oncolytic Bacteria
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy